acebutolol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
beta-adrenoreceptor antagonists	40	37517-30-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: IL-17803A acebutolol HCl acebutolol acebutolol hydrochloride (RS)-Acebutolol (+/-)-Acebutolol dl-Acebutolol	A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action. Molecular weight: 336.43 Formula: C18H28N2O4 CLOGP: 1.71 LIPINSKI: 0 HAC: 6 HDO: 3 TPSA: 87.66 ALOGS: -3.29 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

IL-17803A
acebutolol HCl
acebutolol
acebutolol hydrochloride
(RS)-Acebutolol
(+/-)-Acebutolol
dl-Acebutolol

A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.

Molecular weight: 336.43
Formula: C18H28N2O4
CLOGP: 1.71
LIPINSKI: 0
HAC: 6
HDO: 3
TPSA: 87.66
ALOGS: -3.29
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O
0.40	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	46.09 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	37 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.70 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.74 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 28, 1984	FDA	PROMIUS PHARMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Orthostatic hypotension	964.77	37.11	290	6518	29191	50569125
Sedation complication	950.85	37.11	223	6585	8543	50589773
Cognitive disorder	937.06	37.11	312	6496	43811	50554505
Sedation	898.46	37.11	277	6531	30333	50567983
Creatinine renal clearance decreased	898.39	37.11	226	6582	11655	50586661
Blood calcium decreased	774.00	37.11	226	6582	20480	50577836
Balance disorder	709.94	37.11	288	6520	70302	50528014
Depressed level of consciousness	609.03	37.11	237	6571	51716	50546600
Mobility decreased	542.00	37.11	247	6561	79701	50518615
Hypotension	493.67	37.11	335	6473	235134	50363182
Constipation	453.70	37.11	291	6517	185417	50412899
Fall	407.00	37.11	344	6464	334588	50263728
Toxicity to various agents	357.85	37.11	265	6543	212234	50386082
Pain	94.29	37.11	226	6582	578677	50019639
Multiple drug therapy	84.85	37.11	24	6784	1913	50596403
Diabetes mellitus inadequate control	77.37	37.11	37	6771	13108	50585208
Drug specific antibody	68.28	37.11	20	6788	1805	50596511
Hypocoagulable state	61.66	37.11	16	6792	920	50597396
Endometriosis	59.81	37.11	22	6786	4053	50594263
Blood pressure inadequately controlled	58.26	37.11	22	6786	4358	50593958
Cardiogenic shock	49.31	37.11	29	6779	15570	50582746
Exercise tolerance decreased	49.04	37.11	20	6788	4854	50593462
Fatigue	41.37	37.11	22	6786	707579	49890737
Bradycardia	39.55	37.11	46	6762	64380	50533936
Headache	39.21	37.11	10	6798	506525	50091791
Cor pulmonale acute	38.86	37.11	9	6799	321	50597995
Oesophageal food impaction	38.34	37.11	8	6800	174	50598142

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pancreatic carcinoma metastatic	72.36	24.22	19	1690	2702	29570116
Linear IgA disease	42.63	24.22	11	1698	1458	29571360
Interstitial lung disease	39.44	24.22	30	1679	57688	29515130
Pancreatitis acute	37.26	24.22	21	1688	24364	29548454
Pulmonary fibrosis	36.90	24.22	18	1691	15564	29557254
Ischaemic stroke	33.52	24.22	17	1692	15960	29556858
Cerebral haematoma	30.99	24.22	11	1698	4285	29568533

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sedation complication	997.55	27.23	239	8359	10115	64480019
Cognitive disorder	927.71	27.23	327	8271	54760	64435374
Creatinine renal clearance decreased	918.89	27.23	239	8359	14182	64475952
Orthostatic hypotension	885.36	27.23	303	8295	46435	64443699
Sedation	860.77	27.23	288	8310	41174	64448960
Blood calcium decreased	796.46	27.23	242	8356	25312	64464822
Balance disorder	709.44	27.23	302	8296	83624	64406510
Mobility decreased	563.99	27.23	259	8339	85581	64404553
Depressed level of consciousness	561.10	27.23	254	8344	81182	64408952
Constipation	438.60	27.23	308	8290	229029	64261105
Hypotension	431.76	27.23	375	8223	380599	64109535
Fall	387.14	27.23	367	8231	416459	64073675
Toxicity to various agents	269.92	27.23	284	8314	363229	64126905
Pain	124.54	27.23	245	8353	553266	63936868
Multiple drug therapy	77.10	27.23	23	8575	2231	64487903
Endometriosis	68.15	27.23	22	8576	2770	64487364
Drug specific antibody	65.73	27.23	20	8578	2075	64488059
Diabetes mellitus inadequate control	58.31	27.23	36	8562	21285	64468849
Pancreatic carcinoma metastatic	55.77	27.23	20	8578	3458	64486676
Hypocoagulable state	51.00	27.23	16	8582	1837	64488297
Blood pressure inadequately controlled	50.64	27.23	21	8577	5363	64484771
Cerebral haematoma	44.82	27.23	21	8577	7164	64482970
Bradycardia	40.19	27.23	63	8535	118156	64371978
Fatigue	37.82	27.23	27	8571	748703	63741431
Exercise tolerance decreased	37.47	27.23	19	8579	7691	64482443
Oesophageal food impaction	33.39	27.23	8	8590	334	64489800
Cor pulmonale acute	33.27	27.23	9	8589	613	64489521
Pneumonia	32.65	27.23	17	8581	559559	63930575
Cardiogenic shock	32.48	27.23	30	8568	32397	64457737
Oesophageal achalasia	32.35	27.23	9	8589	681	64489453
Morbid thoughts	31.89	27.23	9	8589	717	64489417
Headache	31.01	27.23	16	8582	529451	63960683
Coma	27.44	27.23	45	8553	87570	64402564

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C07AB04	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, selective
ATC	C07BB04	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Beta blocking agents, selective, and thiazides
FDA MoA	N0000000161	Adrenergic beta-Antagonists
FDA EPC	N0000175556	beta-Adrenergic Blocker
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:35530	beta-adrenergic blockers
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:38070	antiarrhythmic agent
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D058671	Adrenergic beta-1 Receptor Antagonists
MeSH PA	D000319	Adrenergic beta-Antagonists
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D013566	Sympathomimetics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ventricular premature beats	indication	17338001
Hypertensive disorder	indication	38341003	DOID:10763
Anxiety	off-label use	48694002
Thyrotoxicosis	off-label use	90739004	DOID:7997
Angina pectoris	off-label use	194828000
Mitral valve prolapse	off-label use	409712001
Myocardial Reinfarction Prevention	off-label use
Psoriasis	contraindication	9014002	DOID:8893
Complete atrioventricular block	contraindication	27885002
Depressive disorder	contraindication	35489007
Sick sinus syndrome	contraindication	36083008	DOID:13884
Anaphylaxis	contraindication	39579001
Sinus bradycardia	contraindication	49710005
Diabetes mellitus	contraindication	73211009	DOID:9351
Pulmonary emphysema	contraindication	87433001
Cardiogenic shock	contraindication	89138009
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Partial atrioventricular block	contraindication	195039008
Decompensated cardiac failure	contraindication	195111005
Asthma	contraindication	195967001	DOID:2841
Disease of liver	contraindication	235856003	DOID:409
Raynaud's phenomenon	contraindication	266261006
Pregnancy, function	contraindication	289908002
Pheochromocytoma	contraindication	302835009
Severe chronic obstructive pulmonary disease	contraindication	313299006
Peripheral arterial occlusive disease	contraindication	399957001
Peripheral vascular disease	contraindication	400047006
Acute exacerbation of asthma	contraindication	708038006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.19	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	ANTAGONIST	Ki	7.30	WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	6.40	WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		Ki	5	CHEMBL

External reference:

ID	Source
4018063	VUID
N0000179521	NUI
D00597	KEGG_DRUG
34381-68-5	SECONDARY_CAS_RN
142130	RXNORM
C0000946	UMLSCUI
CHEBI:2379	CHEBI
CHEMBL642	ChEMBL_ID
CHEMBL1200813	ChEMBL_ID
DB01193	DRUGBANK_ID
D000070	MESH_DESCRIPTOR_UI
1978	PUBCHEM_CID
7107	IUPHAR_LIGAND_ID
3295	INN_ID
67P356D8GH	UNII
4118	MMSL
64	MMSL
d00128	MMSL
001858	NDDF
004742	NDDF
4018063	VANDF
4019592	VANDF
3597005	SNOMEDCT_US
372815001	SNOMEDCT_US
68088000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Acebutolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-630	CAPSULE	200 mg	ORAL	ANDA	21 sections
Acebutolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-631	CAPSULE	400 mg	ORAL	ANDA	21 sections
Acebutolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50268-050	CAPSULE	200 mg	ORAL	ANDA	13 sections
Acebutolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53746-669	CAPSULE	200 mg	ORAL	ANDA	14 sections
Acebutolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53746-670	CAPSULE	400 mg	ORAL	ANDA	14 sections
Acebutolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4216	CAPSULE	400 mg	ORAL	ANDA	14 sections
Acebutolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5520	CAPSULE	200 mg	ORAL	ANDA	14 sections
Acebutolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	65162-669	CAPSULE	200 mg	ORAL	ANDA	14 sections
Acebutolol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	65162-670	CAPSULE	400 mg	ORAL	ANDA	14 sections
SECTRAL	HUMAN PRESCRIPTION DRUG LABEL	1	67857-700	CAPSULE	200 mg	ORAL	NDA	26 sections
SECTRAL	HUMAN PRESCRIPTION DRUG LABEL	1	67857-701	CAPSULE	400 mg	ORAL	NDA	26 sections